Editorial................................................................................................................................... 1
Program ..................................................................................................................................4
Plenární přednášky .................................................................................................................10
Odborná sympozia
Přínos psychedelik pro výzkum patogeneze schizofrenie a testování antipsychotik ........................11
Serotonin: „hormon štěstí" opět na scéně ...................................................................................12
Praktické aspekty léčby schizofrenie (sympozium České psychiatrické společnosti) ....................14
Neuronální mechanizmy „systému odměny" II ............................................................................15
Léčba antidepresivy v průběhu života ženy ................................................................................16
Panická porucha v průběhu života .............................................................................................17
Psychofarmakologie od dětství do dospělosti ............................................................................19
Duševní poruchy v těhotenství a po porodu, jejich léčba psychofarmaky .......................................20
Farmakorezistence v neuropsychiatrii – a co dál?...................................................................... 21
Poruchy přijmu potravy, biologické faktory a nové poznatky z psychofarmakoterapie .....................22
Hédonizmus a impulzivita: dopaminergně vázané poruchy chování ...............................................23
Dlouhodobý průběh závažných psychických onemocnění (sympozium
Společnosti pro biologickou psychiatrii) .....................................................................................24
Farmakologie a užití amfetaminů – aktuálně ...............................................................................25
Význam současných farmakogenetických aspektů v léčbě psychóz ............................................27
SETKÁNÍ S ODBORNÍKEM ......................................................................................................29
doc. MUDr. Ján Pečeňák, CSc.
doc. MUDr. Klára Látalová, PhD
prof. Jan Volavka, MD, PhD
PRACOVNÍ SNÍDANĚ ČNPS
Využití rTMS v Čechách a na Moravě ......................................................................................30
Nový výzkum
Nový výzkum I – Psychózy .....................................................................................................31
Nový výzkum II – Genetika, metabolizmus a neuropřenašeče ....................................................32
Nový výzkum III – Varia ..........................................................................................................35
Workshopy
Multioborový přístup k psychogenním poruchám motoriky.........................................................37
Diferenciální diagnostika a farmakoterapie demencí II ...............................................................37
Sedmero hlavních hříchů – Lenost ..........................................................................................38
Elektrokonvulzivní terapie .......................................................................................................39
Jak léčit dospělé, kteří byli zneužíváni v dětství .........................................................................39
Patologické truchlení ..............................................................................................................39
Vývěsková sdělení
Klinický výzkum I ..................................................................................................................40
Klinický výzkum II ..................................................................................................................43
Preklinický výzkum ................................................................................................................48
Firemní sympozia ...................................................................................................................59
Jmenný rejstřík...................................................................................................................... 60

Contents

Editorial.................................................................................................................................. 1
Programme .............................................................................................................................4
PLENARY LECTURES ...........................................................................................................10
SCIENTIFIC SYMPOSIA
Contribution of psychedelic drugs to schizophrenia pathophysiology
research and antipsychotic testing ...........................................................................................11
Serotonin: "hormone of happiness" returns ................................................................................12
Practical issues in the treatment of schizophrenia (symposia of Czech Psychiatry
Association) ...........................................................................................................................14

Neuronal mechanisms of the "Reward system" II ........................................................................15
Treatment with antidepressant during the woman life .................................................................. 16
Panic disorder during lifespan ...................................................................................................17
Psychopharmacology from childhood to adult ............................................................................19
Mental disorders in pregnancy and postnatal period and psychiatric
drug treatment of these disorders .............................................................................................20
Pharmacoresistency in neuropsychiatry – what could we do? ......................................................21
Eating disorders, biological factors and new findings in psychopharmacotherapy ...........................22
Hedonism and impulsivity: Dopamine-related behavioural disorder ................................................23
The long-term course of serious mental disorders (Symposium
of the Society of Biological Psychiatry) ......................................................................................24
Pharmacology and use of amphetamines – currently ..................................................................25
Importance of current pharmacogenetic aspects in the treatment of psychosis ..............................27
MEET THE EXPERT ................................................................................................................29
Doc. MUDr. Jan Pecenak, CSc.
Doc. MUDr. Klara Latalova, PhD
Prof. Jan Volavka, MD, PhD
ČNPS BREAKFAST SYMPOSIA
Use of rTMS in Bohemia and Moravia ....................................................................................... 30
NEW RESEARCH
New research I – Psychosis...................................................................................................... 31
New research II – Genetic, metabolism and neurotransmitters .................................................... 32
New research III – Various .......................................................................................................35
WORKSHOPS
Multidisciplinary approach to psychogenic movement disorders....................................................37
Differential diagnosis and pharmacotherapy of dementias II .........................................................37
Seven deadly sins – laziness ...................................................................................................38
Electroconvulsive therapy .........................................................................................................39
Pathological grief .....................................................................................................................39
POSTER SESSIONS
Clinical research I ...................................................................................................................40
Clinical research II ...................................................................................................................43
Pre-clinical research ................................................................................................................48
SPONSORED SATELLITE SYMPOSIA .....................................................................................59
NAME INDEX ..........................................................................................................................60